Lilly Xu

Lilly Xu is an accomplished professional with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as the Chief Technology Officer at Medicilon Inc. since November 2024, Lilly previously held the position of President at ChemPartner from April 2017 to April 2024, managing the CRO business and leading initiatives that generated significant revenue and supported drug discovery for clients. Additionally, Lilly has held various leadership roles at Sanofi, including Head of the Center of Predictive ADMET, and at Amgen and Purdue Pharma, focusing on DMPK and ADMET technologies. Lilly holds a Ph.D. in Cell and Molecular Biology from Saint Louis University School of Medicine.